The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations
Abstract
Objective: To review the literature on efficacy and risks of combining antipsychotics (atypical with atypical or conventional) and suggest a rationale and strategies for future clinical trials. Method: A computerized Medline search supplemented by an examination of cross‐references and reviews was performed. Results: Empirical evidence for the efficacy of combining antipsychotics is too limited to draw firm conclusions. The practice of augmenting clozapine with more ‘tightly bound’ D2 receptor antagonists as exemplified by risperidone augmentation of clozapine has some empirical and theoretical support. The risks of augmentation strategies have not been studied systematically. No study has examined the economic impact of combination treatment. Conclusion: Further trials of antipsychotic combination therapies are needed before this currently unsupported practice can be recommended. Rationales for combination treatment include a broadening of the range of receptor activity or an increase in D2 receptor occupancy with certain atypical agents. Trial methodology needs to take into account subject characteristics, duration of treatment, optimization of monotherapy comparators, and appropriate outcome measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Self-citationKapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Self-citationA Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651
Determining Optimal Therapy — Randomized Trials in Individual Patients
Guyatt, G., Sackett, D., Taylor, D. W., Ghong, J., Roberts, R., & Pugsley, S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604033141406 · Cited by 579
Nordström, A.-L., Farde, L., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527
The Mechanism of Action of Novel Antipsychotic Drugs
Meltzer, H. Y. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.263 · Cited by 411
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370 · cited 1×
“Whereas clozapine and quetiapine are too loosely bound to achieve sustained D2 occupancy above 70%, olanzapine, which has an intermediate dissociation constant, can produce these levels of D2 occupancy at daily doses of approximately 30–40 mg (34).”
BackgroundKapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 267
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.569 · Cited by 260
Staging: a neglected dimension in psychiatric classification
Fava, G. A., & Kellner, R. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03362.x · Cited by 252 · cited 1×
“The issue of staging has received little attention in psychiatry (47).”
BackgroundEvaluation of Treatment-Resistant Schizophrenia
Conley, R. R., & Buchanan, R. W. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.663 · Cited by 238
New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine
Brunello, N. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00068-o · Cited by 191
Clinical Management of Clozapine Patients in Relation to Efficacy and Side-Effects
Naber, D., Holzbach, R., Perro, C., & Hippius, H. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296931 · Cited by 178
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
Bymaster, F. P., Rasmussen, K. G., Calligaro, D. O., NELSON, D. A., DeLapp, N. W., Wong, D. T., & Moore, N. A. (1997) · PubMed · Cited by 162
Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0701 · Cited by 144
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson, D. C., & Goff, D. (1996) · PubMed · Cited by 141
Self-citationThe Genetics of Personality Disorder
McGuffin, P., & Thapar, A. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.1.12 · Cited by 139
Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine?
Baldessarini, R. J., Huston-Lyons, D., Campbell, A., Marsh, E. R., & Cohen, B. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296852 · Cited by 134
The long-term course of the schizophrenic psychoses
Bleule, M. (1974) · Psychological Medicine · doi:10.1017/s0033291700042926 · Cited by 127
Kapur, S., Roy, P., Daskalakis, J. Z., Remington, G. J., & Zipursky, R. B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.311 · Cited by 106
Wang, P. S., West, J. C., Tanielian, T., & Pincus, H. A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033465 · Cited by 92
Clozapine in China: a review and preview of US/PRC collaboration
Potter, W. Z., Ko, G. N., Zhang, L. D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442568 · Cited by 82
Mullen, B., Brar, J. S., Vagnucci, A. H., & Ganguli, R. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00061-x · Cited by 73
Clozapine Augmentation: Safety and Efficacy
Chong, S. A., & Remington, G. J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033463 · Cited by 73
An open trial of risperidone augmentation of partial response to clozapine
Taylor, C. G., Flynn, S. W., Altman, S., Ehmann, T. S., MacEwan, G. W., & Honer, W. G. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00104-3 · Cited by 65
Commentary: Defining Treatment Refractoriness in Schizophrenia
Meltzer, H. Y. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.563 · Cited by 60
Cross-tapering clozapine and risperidone
Koreen, A., Lieberman, J. A., Kronig, M. H., et al. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1690a · Cited by 57
Risperidone Added to Clozapine
Henderson, D. C., GOFF, D. C., Connolly, C. E., Borba, C. P. C., & Hayden, D. L. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0805 · Cited by 45
Self-citationLimitations of controlled augmentation trials in schizophrenia
Stern, R. G., Schmeidler, J., & Davidson, M. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00295-8 · Cited by 24
Thinking Small: Research Designs Appropriate for Clinical Practice
Streiner, D. (1998) · Canadian journal of psychiatry. Revue canadienne de psychiatrie · doi:10.1177/070674379804300709 · Cited by 9
Cited by
Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Metadata
- Authors
- Freudenreich, O., & Goff, D. C.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2002-10-04
- Volume
- 106
- Issue
- 5
- Pages
- 323-330
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2067786055
- Cited by
- 259
- References
- 35
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.